We demonstrated a novel vaccination strategy that uses a live transgenic protozoan parasite-based bivalent vaccine to immunize mice and confer significant levels of protection against VV-gag and malarial parasite challenges.
PCR has proven to be one of the most specific and sensitive diagnostic methods, particularly for malaria cases with low parasitaemia.
We report a case of acute Plasmodium malariae infection complicating corticosteroid treatment for membranoproliferative glomerulonephritis in a patient from an area where P. malariae infection is not endemic.
Mosquito bites transmit liver-tropic sporozoites into subjects who are still infected from a previous mosquito bite. What is the impact of ongoing infection in the establishment of a secondary infection is unknown.
The concept of a malaria vaccine has sparked great interest for decades; however, the challenge is proving to be a difficult one.
The over-replicating wMelPop strain of the endosymbiont Wolbachia pipientis has recently been shown to be capable of inducing immune upregulation and inhibition of pathogen transmission in Aedes aegypti mosquitoes.
Here, we examine the roles of host genetics and exposure in determining parasite density, and test whether effects differ with age.
This is the first study to indicate therapeutic potential of HDAs against various parasitic protozoa. It also points out that the malarial liver stage growth inhibitory effect of the 2-HDA may be promoted via PfFAS-II enzymes.
The data are discussed with respect to the comparative effects on malaria vectorial capacity of life shortening and direct inhibition of Plasmodium development that can be produced by Wolbachia.
Malaria, caused by the apicomplexan parasite Plasmodium, threatens 40% of the world's population. Transmission between vertebrate and insect hosts depends on the sexual stages of the life-cycle.